StemCell Therapy

August 4, 2017 - By Marguerite Chambers

Neuralstem Inc (NASDAQ:CUR) institutional sentiment decreased to 0.3 in Q4 2016. Its down -0.37, from 0.67 in 2016Q3. The ratio worsened, as 8 institutional investors increased or opened new positions, while 27 sold and decreased their stakes in Neuralstem Inc. The institutional investors in our partners database now own: 6.88 million shares, down from 12.30 million shares in 2016Q3. Also, the number of institutional investors holding Neuralstem Inc in their top 10 positions decreased from 1 to 0 for a decrease of 1. Sold All: 16 Reduced: 11 Increased: 6 New Position: 2.

Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $18.31 million. The Firm is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. It currently has negative earnings. The Firm has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.

About 412,558 shares traded or 2.10% up from the average. Neuralstem, Inc. (NASDAQ:CUR) has risen 3.35% since August 4, 2016 and is uptrending. It has underperformed by 13.35% the S&P500.

National Asset Management Inc. holds 0.01% of its portfolio in Neuralstem, Inc. for 167,500 shares. Bank Of America Corp De owns 8,400 shares or 0% of their US portfolio. Moreover, Bank Of New York Mellon Corp has 0% invested in the company for 91,969 shares. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 24,841 shares.#img1#

Since January 1, 0001, it had 3 insider buys, and 0 selling transactions for $70,004 activity.

More important recent Neuralstem, Inc. (NASDAQ:CUR) news were published by: Globenewswire.com which released: Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into on August 02, 2017, also Marketwatch.com published article titled: UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss, Seekingalpha.com published: Neuralstem Is Doomed on August 03, 2017. More interesting news about Neuralstem, Inc. (NASDAQ:CUR) was released by: Benzinga.com and their article: Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares with publication date: July 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read more:
Institutional Investors Lead Shift in Neuralstem Inc (NASDAQ:CUR) Sentiment - BZ Weekly

This entry was posted on August 4, 2017 at 8:47 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |